COMPANY
Eldec Pharmaceuticals
Funding and NIH signals
- SEC Form D raise Raised $200K in debt securities (Form D filed Feb 12, 2026). SEC Form D 0002110508-26-000001 (Feb 12, 2026)
Evidence (1 event)
- Feb 12, 2026 · SEC Form D 0002110508-26-000001
Name of Issuer: Eldec Pharmaceuticals, Inc.; CIK: 2110508; Address: Chapel Hill, NC; Submission type: D; Filing date: 2026-02-12; Industry Group: Pharmaceuticals; Date of First Sale: 2026-02-11; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 1500000; Total Amount Sold: 200000; Federal exemptions: 06b
- Feb 12, 2026 · SEC Form D 0002110508-26-000001
- NIH award NIH awarded $908K (STTR Phase II 4R42DK145320-02, extension, notice Aug 11, 2026). NIH RePORTER 4R42DK145320-02 (Aug 11, 2026)
Evidence (1 event)
- Aug 11, 2026 · NIH RePORTER 4R42DK145320-02
Organization: ELDEC PHARMACEUTICALS, INC.; City/State: Durham, NC; Project number: 4R42DK145320-02; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-11; FY total cost (award amount): 907989; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Novel peptide therapeutics to treat cystic fibrosis-related diabetes; Organization type: Domestic For-Profits
- Aug 11, 2026 · NIH RePORTER 4R42DK145320-02
Timeline
- Grant Government grant — STTR: $907,989 (annual award, as published), announced Aug 11, 2026. Agency: NIH/NIDDK. Source: government award database. source ↗
- Grant Government grant — STTR: $280,122 (annual award, as published), announced Sep 12, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗
Funding
- Government grant — STTR: $907,989 (annual award, as published), announced Aug 11, 2026. Agency: NIH/NIDDK. Source: government award database. source ↗
- Government grant — STTR: $280,122 (annual award, as published), announced Sep 12, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗
NIH awards 9
- NIH award 5R44HL165964-02 FY2023: $977,764 awarded for that fiscal year; activity R44 (SBIR); PI AHMAD, SAIRA; recipient as written: ELDEC PHARMACEUTICALS, INC., Durham, NC. Novel Strategies to Clear Bacteria from th source ↗
- NIH award 1R43AI174395-01 FY2023: $259,121 awarded for that fiscal year; activity R43 (SBIR); PI AHMAD, SAIRA; recipient as written: ELDEC PHARMACEUTICALS, INC., Durham, NC. Novel Peptide Immunomodulators for Treatin source ↗
- NIH award 3R44HL165964-01S1 FY2023: $94,743 awarded for that fiscal year; activity R44 (SBIR); PI AHMAD, SAIRA; recipient as written: ELDEC PHARMACEUTICALS, INC., Durham, NC. Novel Strategies to Clear Bacteria from t source ↗
- NIH award 1R41AI162083-01A1 FY2022: $300,000 awarded for that fiscal year; activity R41 (STTR); PI TARRAN, ROBERT; recipient as written: ELDEC PHARMACEUTICALS, INC., Durham, NC. Novel Peptide Fusion Inhibitors for th source ↗
- NIH award 1R44HL165964-01 FY2022: $999,919 awarded for that fiscal year; activity R44 (SBIR); PI AHMAD, SAIRA; recipient as written: ELDEC PHARMACEUTICALS, INC., Durham, NC. Novel Strategies to Clear Bacteria from th source ↗
- NIH award 5R42AI155107-03 FY2022: $988,238 awarded for that fiscal year; activity R42 (STTR); PI TARRAN, ROBERT; recipient as written: ELDEC PHARMACEUTICALS, INC., Durham, NC. ELD607 Orai1 Antagonist Increases Bacter source ↗
- NIH award 4R42AI155107-02 FY2021: $999,840 awarded for that fiscal year; activity R42 (STTR); PI TARRAN, ROBERT; recipient as written: ELDEC PHARMACEUTICALS, INC., Durham, NC. ELD607 Orai1 Antagonist Increases Bacter source ↗
- NIH award 1R42AI155107-01 FY2020: $300,000 awarded for that fiscal year; activity R42 (STTR); PI TARRAN, ROBERT; recipient as written: ELDEC PHARMACEUTICALS, INC., Durham, NC. ELD607 Orai1 Antagonist Increases Bacter source ↗
- NIH award 1R43HL144290-01 FY2018: $224,865 awarded for that fiscal year; activity R43 (SBIR); PI SHEA, RICHARD JOSEPH; recipient as written: ELDEC PHARMACEUTICALS, INC., Durham, NC. Peptide therapies for treating CF source ↗